LUNG CANCER DIAGNOSTIC AND SCREENING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Lung Cancer Diagnostic and Screening Market, By Test Type (Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others) Imaging Test (Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy), By Cancer Type (Non-small cell lung cancer, Small Cell Lung CancerNeurosurgery), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In: 25 Mar, 2025
Code: CMI4434
Pages: 180
Formats: Excel and PDF
Industry: Clinical Diagnostic
- Historical Range: 2020 - 2024
- Forecast Period: 2025 - 2032

Lung cancer begins in the lungs and may spread to lymph nodes or other organs in the body, such as the brain. Cancer from other organs also may spread to the lungs. When cancer cells spread from one organ to another, they are called metastases. Lung cancers usually are grouped into two main types such as small cell and non-small cell. These types of lung cancer grow differently and are treated differently. According American Cancer Society non-small cell lung cancer is more common than small cell lung cancer. Different people have different symptoms for lung cancer. Some people have symptoms related to the lungs. Some people whose lung cancer has spread to other parts of the body (metastasized) have symptoms specific to that part of the body. Lung cancer symptoms may include coughing that gets worse or prolonged coughing, chest pain, shortness of breath, wheezing, coughing of blood, feeling very tired all the time, weight loss with no known cause.

According to the Centers for Disease Control and Prevention, lung cancer is the third most common cancer in the U.S. Most people in the U.S. die from lung cancer than any other type of cancer. For instance, According American Cancer Society, an estimated 154,050 Americans were expected to die from lung cancer in 2018, accounting for approximately 25% of all cancer deaths. Doctors may perform several tests to confirm lung cancer such as biomarker test, imaging test, and biopsy.

Market Dynamics

Regulatory approvals and launches of new screening test are expected to propel growth of the global lung cancer diagnostic and screening market during the forecast period. For instance, in August 2020, the U.S. Food and Drug Administration approved the liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC).

However, high cost of lung cancer screening test is also expected to limit the market growth. For instance, according to the American Board of International medicine a CT scan costs US$ 300 and more. These test one need to take periodically.

Key features of the study:

This report provides in-depth analysis of the global lung cancer diagnostic and screening market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global lung cancer diagnostic and screening market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Abbott, Illumina, Inc, Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics, Inc. F. Hoffmann-La Roche Ltd., Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global lung cancer diagnostic and screening market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for lung cancer diagnostic and screening market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

Global Lung Cancer Diagnostic and Screening market, By Test Type:
- Biomarkers Tests
  - EGFR Mutation Test
  - KRAS Mutation Test
  - ALK Test
  - HER2 Test
  - Others
- Imaging Tests
  - Computed Tomography (CT) Scan
  - Positron Emission Tomography (PET) Scan
  - Chest X-RAY
  - Others
- Biopsy
  - Needle Biopsy
  - Bronchoscopy Biopsy
  - Open Biopsy
  - Others

Global Lung Cancer Diagnostic and Screening Market, By Cancer Type:
- Non-small cell lung cancer
- Small Cell Lung Cancer
Global Lung Cancer Diagnostic and Screening Market, By End User:
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
Global Lung Cancer Diagnostic and Screening Market, By Region:
- North America
  - By Country:
    - U.S.
    - Canada
  - By Test Type:
    - Biomarkers Tests
      - EGFR Mutation Test
      - KRAS Mutation Test
      - ALK Test
      - HER2 Test
      - Others
    - Imaging Tests
      - Computed Tomography (CT) Scan
      - Positron Emission Tomography (PET) Scan
      - Chest X-RAY
      - Others
    - Biopsy
      - Needle Biopsy
      - Bronchoscopy Biopsy
      - Open Biopsy
      - Others
  - By Cancer Type:
    - Non-small cell lung cancer
    - Small Cell Lung Cancer
  - By End User:
    - Hospitals
    - Independent Diagnostic Laboratories
    - Diagnostic Imaging Centers
    - Cancer Research Institutes
- Europe
  - By Country:
    - U.K.
    - Germany
    - Italy
    - Spain
    - France
    - Russia
    - Rest of Europe
  - By Test Type:
    - Biomarkers Tests
      - EGFR Mutation Test
      - KRAS Mutation Test
      - ALK Test
      - HER2 Test
      - Others
    - Imaging Tests
      - Computed Tomography (CT) Scan
      - Positron Emission Tomography (PET) Scan
      - Chest X-RAY
      - Others
    - Biopsy
      - Needle Biopsy
      - Bronchoscopy Biopsy
      - Open Biopsy
      - Others
  - By Cancer Type:
    - Non-small cell lung cancer
    - Small Cell Lung Cancer
  - By End User:
    - Hospitals
    - Independent Diagnostic Laboratories
    - Diagnostic Imaging Centers
    - Cancer Research Institutes
- Asia Pacific
  - By Country:
    - Australia
    - India
    - China
    - Japan
    - ASEAN
    - South Korea
    - Rest of Asia Pacific
  - By Test Type:
    - Biomarkers Tests
      - EGFR Mutation Test
      - KRAS Mutation Test
      - ALK Test
      - HER2 Test
      - Others
    - Imaging Tests
      - Computed Tomography (CT) Scan
      - Positron Emission Tomography (PET) Scan
      - Chest X-RAY
      - Others
    - Biopsy
      - Needle Biopsy
      - Bronchoscopy Biopsy
      - Open Biopsy
      - Others
  - By Cancer Type:
    - Non-small cell lung cancer
    - Small Cell Lung Cancer
  - By End User:
    - Hospitals
    - Independent Diagnostic Laboratories
    - Diagnostic Imaging Centers
    - Cancer Research Institutes
- Latin America
  - By Country:
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
  - By Test Type:
    - Biomarkers Tests
      - EGFR Mutation Test
      - KRAS Mutation Test
      - ALK Test
      - HER2 Test
      - Others
    - Imaging Tests
      - Computed Tomography (CT) Scan
      - Positron Emission Tomography (PET) Scan
      - Chest X-RAY
      - Others
    - Biopsy
      - Needle Biopsy
      - Bronchoscopy Biopsy
      - Open Biopsy
      - Others
  - By Cancer Type:
    - Non-small cell lung cancer
    - Small Cell Lung Cancer
  - By End User:
    - Hospitals
    - Independent Diagnostic Laboratories
    - Diagnostic Imaging Centers
    - Cancer Research Institutes
- Middle East
  - By Country:
    - GCC
    - Israel
    - Rest of Middle East
  - By Test Type:
    - Biomarkers Tests
      - EGFR Mutation Test
      - KRAS Mutation Test
      - ALK Test
      - HER2 Test
      - Others
    - Imaging Tests
      - Computed Tomography (CT) Scan
      - Positron Emission Tomography (PET) Scan
      - Chest X-RAY
      - Others
    - Biopsy
      - Needle Biopsy
      - Bronchoscopy Biopsy
      - Open Biopsy
      - Others
  - By Cancer Type:
    - Non-small cell lung cancer
    - Small Cell Lung Cancer
  - By End User:
    - Hospitals
    - Independent Diagnostic Laboratories
    - Diagnostic Imaging Centers
    - Cancer Research Institutes
- Africa
  - By Country/Region:
    - South Africa
    - Central Africa
    - North Africa
  - By Test Type:
    - Biomarkers Tests
      - EGFR Mutation Test
      - KRAS Mutation Test
      - ALK Test
      - HER2 Test
      - Others
    - Imaging Tests
      - Computed Tomography (CT) Scan
      - Positron Emission Tomography (PET) Scan
      - Chest X-RAY
      - Others
    - Biopsy
      - Needle Biopsy
      - Bronchoscopy Biopsy
      - Open Biopsy
      - Others
  - By Cancer Type:
    - Non-small cell lung cancer
    - Small Cell Lung Cancer
  - By End User:
    - Hospitals
    - Independent Diagnostic Laboratories
    - Diagnostic Imaging Centers
    - Cancer Research Institutes
Company Profiles
- Abbott
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Illumina, Inc
- Thermo Fischer Scientific
- QIAGEN
- Quest Diagnostics Incorporated
- NeoGenomics
- NanoString
- Myriad Genetics, Inc.
- Hoffmann-La Roche Ltd
- Danaher
- Agilent Technologies, Inc.
- AstraZeneca
- Sanofi
- Janssen Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Global Lung Cancer Diagnostic and Screening Market Detailed Segmentation:

By Test Type:
- EGFR Mutation Test
- KRAS Mutation Test
- ALK Test
- HER2 Test
- Others
- Computed Tomography (CT) scan
- Positron Emission Tomography (PET) scan
- Chest X-Ray
- Others

Biomarkers Test
Imaging Test
Biopsy

By Cancer Type:
- Non-small cell lung cancer
- Small Cell Lung Cancer
By End User:
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Cancer Research Institutes
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa

Limited Time Offer - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Download Free Sample Framework of Entire Report (Version 2025)

Interest is driven by :

Business Use – Evaluate our sample report before buying the full report

Personal Use – Explore a sample report to build knowledge

I'm not a robot

reCAPTCHA

Privacy - Terms

I acknowledge that I have read the Privacy Policy

What's Inside the Sample Report?

Current Industry Events of 2025, and Its Impact on the Market
Market Size Estimation – Historical (2020–2024), Current (2025), and Forecast (2025–2032)
Regional Breakdown – North America, Europe, Asia Pacific, Middle East, Africa, and Latin America
Country-Level Analysis – Independent cross segmental analysis across 35 countries.
Competitive Landscape – Company market share analysis, product benchmarking, and detailed Company Profiles for more than 25+ players.
Customer Intelligence – Customers profiles of more than 50 Customers
Segmental Analysis – Market Size, Y-o-Y growth rate, Trends, and use-cases across more than 5 segments, and 25 sub-segments.
Pricing Analysis – Pricing Dashboard, by geographies and by Companies.
Sustainability & Innovation Strategies – Green trends and ESG practices
Key Market Drivers, Challenges & Future Trends – Impact analysis on growth
Customized Insights Section tailored to client-specific questions or industry focus.
Future Outlook – Forecast, future positioning of companies, and futuristic trends.

LUNG CANCER DIAGNOSTIC AND SCREENING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global Lung Cancer Diagnostic and Screening Market Detailed Segmentation:

By Test Type:

By Cancer Type:

By End User:

By Region:

EXISTING CLIENTELE

Sales Office (U.S.) :

Menu

Reader Club

Help

Connect With Us :

Secure Payment By :